Horizon Therapeutics Investor Sues To Halt $28B Amgen Deal
Biopharmaceutical company Horizon Therapeutics PLC and the members of its board have been hit with a shareholder suit alleging they failed to supply investors with critical information about its proposed $27.8...To view the full article, register now.
Already a subscriber? Click here to view full article